Pharmacological options for the treatment of chronic migraine pain

被引：4

作者：

Urits, Ivan ^{[1
]}

Gress, Kyle ^{[2
]}

Charipova, Karina ^{[2
]}

Zamarripa, Alec M. ^{[3
]}

Patel, Parth M. ^{[3
]}

Lassiter, Grace ^{[2
]}

Jung, Jai Won ^{[2
]}

Kaye, Alan D. ^{[4
]}

Viswanath, Omar ^{[3
,4
,5
,6
]}

机构：

[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA

[2] Georgetown Univ, Sch Med, Washington, DC USA

[3] Univ Arizona, Dept Anesthesiol, Coll Med Phoenix, Phoenix, AZ USA

[4] Louisiana State Univ Hlth Shreveport, Dept Anesthesiol, Shreveport, LA USA

[5] Creighton Univ, Sch Med, Dept Anesthesiol, Omaha, NE USA

[6] Valley Pain Consultants Envision Phys Serv, Phoenix, AZ USA

来源：

BEST PRACTICE & RESEARCH-CLINICAL ANAESTHESIOLOGY | 2020年 / 34卷 / 03期

关键词：

migraine; preventive therapy; chronic pain; pharmacology; therapeutics; TOXIN TYPE-A; QUALITY STANDARDS SUBCOMMITTEE; LONG-TERM SAFETY; DOUBLE-BLIND; PREVENTIVE TREATMENT; PROPHYLACTIC TREATMENT; ANTINOCICEPTIVE ACTION; CENTRAL SENSITIZATION; ANTIEPILEPTIC DRUGS; ENERGY-METABOLISM;

D O I：

10.1016/j.bpa.2020.08.002

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

Migraine is a debilitating neurological condition with symptoms typically consisting of unilateral and pulsating headache, sensitivity to sensory stimuli, nausea, and vomiting. The World Health Organization (WHO) reports that migraine is the third most prevalent medical disorder and second most disabling neurological condition in the world. There are several options for preventive migraine treatments that include, but are not limited to, anticonvulsants, antidepressants, beta blockers, calcium channel blockers, botulinum toxins, NSAIDs, riboflavin, and magnesium. Patients may also benefit from adjunct nonpharmacological options in the comprehensive prevention of migraines, such as cognitive behavior therapy, relaxation therapies, biofeedback, lifestyle guidance, and education. Preventative therapies are an essential component of the overall approach to the pharmacological treatment of migraine. Comparative studies of newer therapies are needed to help patients receive the best treatment option for chronic migraine pain. (C) 2020 Published by Elsevier Ltd.

引用

页码：383 / 407

页数：25

共 144 条

[1] Headache disorders: differentiating and managing the common subtypes [J].

Ahmed, Fayyaz .

BRITISH JOURNAL OF PAIN, 2012, 6 (03) :124-132

[2] Targeting the central projection of the dural trigeminovascular system for migraine prophylaxis [J].

Akerman, Simon ;

Romero-Reyes, Marcela .

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2019, 39 (04) :704-717

[3] Histamine in Migraine and Brain [J].

Alstadhaug, Karl B. .

HEADACHE, 2014, 54 (02) :246-259

[4] Topiramate in the treatment of migraine: A kainate (glutamate) receptor antagonist within the trigeminothalamic pathway [J].

Andreou, Anna P. ;

Goadsby, Peter J. .

CEPHALALGIA, 2011, 31 (13) :1343-1358

[5]

[Anonymous], 2019, CURR PAIN HEADACHE R

[6] Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A [J].

Aoki, KR .

NEUROTOXICOLOGY, 2005, 26 (05) :785-793

[7] Nitric oxide-induced headache in patients with chronic tension-type headache [J].

Ashina, M ;

Bendtsen, L ;

Jensen, R ;

Olesen, J .

BRAIN, 2000, 123 :1830-1837

[8] Zonisamide for migraine prophylaxis in refractory patients [J].

Ashkenazi, A. ;

Benlifer, A. ;

Korenblit, J. ;

Silberstein, S. D. .

CEPHALALGIA, 2006, 26 (10) :1199-1202

[9]

Assarzadegan F, 2017, IRAN J PHARM RES, V16, P788

[10] Is chronic migraine one end of a spectrum of migraine or a separate entity? [J].

Aurora, S. K. .

CEPHALALGIA, 2009, 29 (06) :597-605

← 1 2 3 4 5 6 7 8 9 10 →